1,5-bis(2-methoxyphenyl)penta-1,4-dien-3-one is a complex organic molecule with a specific structure and characteristics. Here's a breakdown of its features and potential research significance:
**Structure and Properties:**
* **Name:** The name itself provides clues to its structure.
* **bis(2-methoxyphenyl)** indicates two 2-methoxyphenyl groups (also known as ortho-methoxyphenyl) are present. These groups consist of a benzene ring with a methoxy (CH3O) group attached at the second position.
* **penta-1,4-dien-3-one** refers to a five-carbon chain (penta) with double bonds at positions 1 and 4 (dien) and a ketone (C=O) group at position 3.
* **Overall:** This molecule likely resembles a long chain with two aromatic rings (2-methoxyphenyl) attached at each end.
**Potential Research Significance:**
The specific importance of this molecule depends on the research context. However, its structure suggests potential areas of interest:
* **Medicinal Chemistry:**
* **Pharmacological Activity:** The presence of aromatic rings and a ketone group suggests potential for biological activity. These structures are common in pharmaceuticals, potentially interacting with biological targets like enzymes or receptors.
* **Drug Design:** This molecule could be a starting point for designing new drugs by modifying its structure to enhance specific properties like potency, selectivity, or bioavailability.
* **Materials Science:**
* **Organic Electronics:** The conjugated structure (alternating double and single bonds) could make this molecule suitable for use in organic electronics applications.
* **Photochemistry:** The presence of the ketone and aromatic rings may give the molecule interesting photochemical properties, potentially useful in solar cells or photocatalysis.
* **Synthetic Chemistry:**
* **New Synthesis Routes:** Developing methods to synthesize this molecule could lead to the discovery of novel synthetic pathways for related compounds.
* **Reactivity Studies:** Investigating the molecule's reactivity and its reactions with other chemicals can contribute to understanding its stability and potential applications.
**Important Note:** Without additional information, such as research papers or specific research questions, it's impossible to definitively say why this molecule is important for research.
**To find more information, you can:**
* **Search for publications:** Use scientific databases like PubMed, SciFinder, or Google Scholar to search for research papers that mention this molecule.
* **Check chemical databases:** Websites like PubChem or ChemSpider can provide information about the molecule's structure, properties, and potential uses.
* **Contact researchers:** If you have access to researchers in relevant fields (medicinal chemistry, materials science, etc.), you can reach out to them for specific insights.
1,5-bis(2-methoxyphenyl)penta-1,4-dien-3-one: has antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 263454 |
CHEMBL ID | 1733734 |
MeSH ID | M0577818 |
Synonym |
---|
smr001570138 |
mls002703419 , |
NCIOPEN2_006455 |
1,5-bis(2-methoxyphenyl)penta-1,4-dien-3-one |
1,5-bis(2-methoxyphenyl)-3-penta-1,4-dienone |
bdbm94600 |
cid_263454 |
1,5-bis(2-methoxyphenyl)-1,4-pentadien-3-one |
RCZMPCUUTSDNAJ-UHFFFAOYSA-N |
CHEMBL1733734 |
FT-0698741 |
bis-(2-methoxybenzal)acetone |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Nrf2 | Homo sapiens (human) | Potency | 1.5849 | 0.0920 | 8.2222 | 23.1093 | AID624171 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 28.1838 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
ClpP | Bacillus subtilis | Potency | 28.1838 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
TDP1 protein | Homo sapiens (human) | Potency | 3.9376 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Smad3 | Homo sapiens (human) | Potency | 10.0000 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
67.9K protein | Vaccinia virus | Potency | 19.0919 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
IDH1 | Homo sapiens (human) | Potency | 18.3564 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 35.4813 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 29.0929 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 22.3872 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
geminin | Homo sapiens (human) | Potency | 5.7319 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 4.8062 | 0.0580 | 10.6949 | 26.6086 | AID602310; AID651812; AID651813 |
DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 4.3797 | 0.0259 | 11.2398 | 31.6228 | AID602313; AID651814; AID651815 |
Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 2.2387 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 50.1187 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 2.2387 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
hepatocyte nuclear factor 4-alpha isoform 2 | Homo sapiens (human) | IC50 (µMol) | 6.4640 | 1.4170 | 5.0866 | 7.8660 | AID651720 |
perilipin-5 | Homo sapiens (human) | IC50 (µMol) | 5.7115 | 0.9850 | 3.4565 | 9.4680 | AID651677; AID651733 |
perilipin-1 | Homo sapiens (human) | IC50 (µMol) | 5.3430 | 0.9250 | 3.3033 | 9.6190 | AID651672 |
1-acylglycerol-3-phosphate O-acyltransferase ABHD5 isoform a | Homo sapiens (human) | IC50 (µMol) | 5.7115 | 0.9250 | 3.5828 | 9.6190 | AID651677; AID651733 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |